Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma.
Jennifer A FoltzBrian T HessVeronika BachanovaNancy L BartlettMelissa M Berrien-ElliottEthan McClainMichelle Becker-HapakMark FosterTimothy SchappeBrad KahlNeha Mehta-ShahAmanda F CashenNancy D MarinKristen McDanielsChaz MorenoMatthew MosiorFeng GaoMalachi GriffithMalachi GriffithJulia A WagnerNarendranath EpperlaAmy D RockJohn LeeAllegra A PettiPatrick Soon-ShiongTodd A FehnigerPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
N-803 combines with mAbs to enhance tumor targeting in patients, and warrants further investigation in combination with immunotherapies.